$XCUR
Exicure Inc

2020 Q2 Form 10-Q Financial Statement

#000169853020000059 Filed on August 12, 2020

View on sec.gov

Income Statement

Concept 2020 Q2 2019 Q2
Revenue $4.847M $434.0K
YoY Change 1016.82% 2184.21%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.230M $1.990M
YoY Change 12.06% 0.0%
% of Gross Profit
Research & Development $7.008M $3.433M
YoY Change 104.14% -10.48%
% of Gross Profit
Depreciation & Amortization $190.0K $80.00K
YoY Change 137.5% -11.11%
% of Gross Profit
Operating Expenses $9.237M $5.418M
YoY Change 70.49% -6.96%
Operating Profit -$4.390M -$4.984M
YoY Change -11.92% -14.13%
Interest Expense $0.00 $203.0K
YoY Change -100.0% 22.29%
% of Operating Profit
Other Income/Expense, Net $79.00K -$236.0K
YoY Change -133.47% -76.89%
Pretax Income -$4.310M -$5.220M
YoY Change -17.43% -23.57%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$4.311M -$5.220M
YoY Change -17.41% -23.52%
Net Earnings / Revenue -88.94% -1202.76%
Basic Earnings Per Share -$0.05
Diluted Earnings Per Share -$0.05 -$117.6K
COMMON SHARES
Basic Shares Outstanding 87.17M shares 44.37M shares
Diluted Shares Outstanding 87.17M shares

Balance Sheet

Concept 2020 Q2 2019 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $85.80M $17.20M
YoY Change 398.84% 4.88%
Cash & Equivalents $17.20M $17.18M
Short-Term Investments $68.60M
Other Short-Term Assets $3.400M $1.600M
YoY Change 112.5% 0.0%
Inventory
Prepaid Expenses $2.203M $795.0K
Receivables $21.00K $0.00
Other Receivables $200.0K $0.00
Total Short-Term Assets $89.39M $18.76M
YoY Change 376.49% 3.8%
LONG-TERM ASSETS
Property, Plant & Equipment $4.464M $963.0K
YoY Change 363.55% -20.15%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $2.266M $533.0K
YoY Change 325.14% 732.81%
Total Long-Term Assets $6.730M $1.496M
YoY Change 349.87% 17.8%
TOTAL ASSETS
Total Short-Term Assets $89.39M $18.76M
Total Long-Term Assets $6.730M $1.496M
Total Assets $96.12M $20.26M
YoY Change 374.52% 4.72%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.540M $917.0K
YoY Change 67.94% -12.25%
Accrued Expenses $1.947M $1.781M
YoY Change 9.32% 7.81%
Deferred Revenue $541.0K
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $4.859M
YoY Change -100.0% 209.49%
Total Short-Term Liabilities $14.37M $8.098M
YoY Change 77.41% 89.78%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities $0.00 $226.0K
YoY Change -100.0% -17.82%
Total Long-Term Liabilities $0.00 $226.0K
YoY Change -100.0% -93.74%
TOTAL LIABILITIES
Total Short-Term Liabilities $14.37M $8.098M
Total Long-Term Liabilities $0.00 $226.0K
Total Liabilities $14.37M $8.865M
YoY Change 62.06% -6.1%
SHAREHOLDERS EQUITY
Retained Earnings -$84.46M -$65.50M
YoY Change 28.94% 45.83%
Common Stock $9.000K $4.000K
YoY Change 125.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $81.75M $11.39M
YoY Change
Total Liabilities & Shareholders Equity $96.12M $20.26M
YoY Change 374.52% 4.72%

Cashflow Statement

Concept 2020 Q2 2019 Q2
OPERATING ACTIVITIES
Net Income -$4.311M -$5.220M
YoY Change -17.41% -23.52%
Depreciation, Depletion And Amortization $190.0K $80.00K
YoY Change 137.5% -11.11%
Cash From Operating Activities -$10.96M -$4.990M
YoY Change 119.64% 6.62%
INVESTING ACTIVITIES
Capital Expenditures -$2.420M -$50.00K
YoY Change 4740.0% -16.67%
Acquisitions
YoY Change
Other Investing Activities $5.960M
YoY Change
Cash From Investing Activities $3.530M -$50.00K
YoY Change -7160.0% -16.67%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 50.00K 10.00K
YoY Change 400.0%
NET CHANGE
Cash From Operating Activities -10.96M -4.990M
Cash From Investing Activities 3.530M -50.00K
Cash From Financing Activities 50.00K 10.00K
Net Change In Cash -7.380M -5.030M
YoY Change 46.72% 6.12%
FREE CASH FLOW
Cash From Operating Activities -$10.96M -$4.990M
Capital Expenditures -$2.420M -$50.00K
Free Cash Flow -$8.540M -$4.940M
YoY Change 72.87% 6.93%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001698530
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
CY2020Q2 xcur Operating Lease Asset Remaining Useful Life
OperatingLeaseAssetRemainingUsefulLife
P0Y
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2020-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39011
dei Entity Registrant Name
EntityRegistrantName
EXICURE, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Address City Or Town
EntityAddressCityOrTown
Chicago
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
81-5333008
dei Entity Address Address Line1
EntityAddressAddressLine1
2430 N. Halsted St.
dei Entity Address State Or Province
EntityAddressStateOrProvince
IL
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
60614
dei City Area Code
CityAreaCode
(847)
dei Local Phone Number
LocalPhoneNumber
673-1700
dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
dei Trading Symbol
TradingSymbol
XCUR
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
dei Entity Shell Company
EntityShellCompany
false
CY2020Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
87228586 shares
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17198000 USD
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17198000 USD
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
48460000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
48460000 USD
CY2020Q2 us-gaap Short Term Investments
ShortTermInvestments
68579000 USD
CY2019Q4 us-gaap Short Term Investments
ShortTermInvestments
62326000 USD
CY2020Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
21000 USD
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
16000 USD
CY2020Q2 us-gaap Unbilled Receivables Current
UnbilledReceivablesCurrent
3000 USD
CY2019Q4 us-gaap Unbilled Receivables Current
UnbilledReceivablesCurrent
19000 USD
CY2020Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3588000 USD
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1955000 USD
CY2020Q2 us-gaap Assets Current
AssetsCurrent
89389000 USD
CY2019Q4 us-gaap Assets Current
AssetsCurrent
112776000 USD
CY2020Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4464000 USD
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2099000 USD
CY2020Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2266000 USD
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
388000 USD
CY2020Q2 us-gaap Assets
Assets
96119000 USD
CY2019Q4 us-gaap Assets
Assets
115263000 USD
CY2020Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
0 USD
CY2019Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
4965000 USD
CY2020Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1540000 USD
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1814000 USD
CY2020Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1947000 USD
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2435000 USD
CY2019Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
21873000 USD
CY2020Q2 us-gaap Liabilities Current
LiabilitiesCurrent
14367000 USD
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
31087000 USD
CY2020Q2 xcur Common Stock Warrant Liability
CommonStockWarrantLiability
0 USD
CY2019Q4 xcur Common Stock Warrant Liability
CommonStockWarrantLiability
414000 USD
CY2020Q2 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
0 USD
CY2019Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
2956000 USD
CY2020Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
0 USD
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
59000 USD
CY2020Q2 us-gaap Liabilities
Liabilities
14367000 USD
CY2019Q4 us-gaap Liabilities
Liabilities
34516000 USD
CY2020Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2020Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2020Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
87206346 shares
CY2020Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
87206346 shares
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
86069263 shares
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
86069263 shares
CY2020Q2 us-gaap Common Stock Value
CommonStockValue
9000 USD
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
9000 USD
CY2020Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
165863000 USD
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
162062000 USD
CY2020Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
338000 USD
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-27000 USD
CY2020Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-84458000 USD
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-81297000 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
81752000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
80747000 USD
CY2020Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
96119000 USD
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
115263000 USD
CY2020Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4847000 USD
CY2019Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
434000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
14030000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
459000 USD
CY2020Q2 us-gaap Revenues
Revenues
4847000 USD
CY2019Q2 us-gaap Revenues
Revenues
434000 USD
us-gaap Revenues
Revenues
14030000 USD
us-gaap Revenues
Revenues
459000 USD
CY2020Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7008000 USD
CY2019Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3433000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13083000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6828000 USD
CY2020Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2229000 USD
CY2019Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1985000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4803000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4193000 USD
CY2020Q2 us-gaap Operating Expenses
OperatingExpenses
9237000 USD
CY2019Q2 us-gaap Operating Expenses
OperatingExpenses
5418000 USD
us-gaap Operating Expenses
OperatingExpenses
17886000 USD
us-gaap Operating Expenses
OperatingExpenses
11021000 USD
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-4390000 USD
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-4984000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-3856000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-10562000 USD
CY2020Q2 us-gaap Investment Income Dividend
InvestmentIncomeDividend
4000 USD
CY2019Q2 us-gaap Investment Income Dividend
InvestmentIncomeDividend
82000 USD
us-gaap Investment Income Dividend
InvestmentIncomeDividend
43000 USD
us-gaap Investment Income Dividend
InvestmentIncomeDividend
187000 USD
CY2020Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
267000 USD
CY2019Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
1000 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
627000 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
2000 USD
CY2020Q2 us-gaap Interest Expense
InterestExpense
0 USD
CY2019Q2 us-gaap Interest Expense
InterestExpense
203000 USD
us-gaap Interest Expense
InterestExpense
128000 USD
us-gaap Interest Expense
InterestExpense
386000 USD
CY2020Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-192000 USD
CY2019Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-116000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
153000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
253000 USD
CY2020Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
79000 USD
CY2019Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-236000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
695000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
56000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-4311000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-4311000 USD
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-5220000 USD
us-gaap Net Income Loss
NetIncomeLoss
-3161000 USD
us-gaap Net Income Loss
NetIncomeLoss
-10506000 USD
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.05
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.12
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.04
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.24
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
87174533 shares
CY2019Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
44368174 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
87126847 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
44363115 shares
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-4311000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-4311000 USD
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-5220000 USD
us-gaap Net Income Loss
NetIncomeLoss
-3161000 USD
us-gaap Net Income Loss
NetIncomeLoss
-10506000 USD
CY2020Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
355000 USD
CY2019Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
0 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
365000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
0 USD
CY2020Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
355000 USD
CY2019Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
0 USD
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
365000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
0 USD
CY2020Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3956000 USD
CY2019Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5220000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2796000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10506000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
80747000 USD
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
441000 USD
CY2020Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2766000 USD
CY2020Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
10000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
1150000 USD
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
85114000 USD
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
50000 USD
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
544000 USD
CY2020Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
355000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-4311000 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
81752000 USD
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
20952000 USD
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
489000 USD
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-5286000 USD
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
16155000 USD
CY2019Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
17000 USD
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
439000 USD
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-5220000 USD
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
11391000 USD
us-gaap Net Income Loss
NetIncomeLoss
-3161000 USD
us-gaap Net Income Loss
NetIncomeLoss
-10506000 USD
us-gaap Depreciation Amortization And Accretion Net
DepreciationAmortizationAndAccretionNet
335000 USD
us-gaap Depreciation Amortization And Accretion Net
DepreciationAmortizationAndAccretionNet
174000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
985000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
928000 USD
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
35000 USD
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
86000 USD
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
356000 USD
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
36000 USD
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-157000 USD
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-256000 USD
us-gaap Increase Decrease In Contract With Customer Asset
IncreaseDecreaseInContractWithCustomerAsset
-11000 USD
us-gaap Increase Decrease In Contract With Customer Asset
IncreaseDecreaseInContractWithCustomerAsset
-3000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1551000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
257000 USD
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
1034000 USD
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-112000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
22000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
403000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-647000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-66000 USD
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-13949000 USD
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
541000 USD
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-59000 USD
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-194000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-18814000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8996000 USD
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
38072000 USD
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
0 USD
us-gaap Proceeds From Sale And Maturity Of Other Investments
ProceedsFromSaleAndMaturityOfOtherInvestments
32103000 USD
us-gaap Proceeds From Sale And Maturity Of Other Investments
ProceedsFromSaleAndMaturityOfOtherInvestments
0 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2996000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
62000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-8965000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-62000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2973000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
50000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
17000 USD
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
4999000 USD
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
0 USD
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
100000 USD
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
52000 USD
xcur Payments Of Common Stock Financing Costs
PaymentsOfCommonStockFinancingCosts
207000 USD
xcur Payments Of Common Stock Financing Costs
PaymentsOfCommonStockFinancingCosts
0 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-2283000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-35000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-30062000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-9093000 USD
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
48460000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
48460000 USD
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
26268000 USD
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
18398000 USD
CY2019Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
17175000 USD
us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
0 USD
us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
100000 USD
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
60000 USD
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
14000 USD
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17198000 USD
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17198000 USD
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
48460000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
48460000 USD
CY2020Q2 us-gaap Restricted Cash
RestrictedCash
1200000 USD
CY2019Q4 us-gaap Restricted Cash
RestrictedCash
0 USD
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
18398000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
48460000 USD
xcur Lessee Operating Lease Lease Not Yet Commenced Lease Area
LesseeOperatingLeaseLeaseNotYetCommencedLeaseArea
30000 sqft
CY2020Q2 xcur Retained Earnings Accumulated Deficit Inceptionto Date
RetainedEarningsAccumulatedDeficitInceptiontoDate
-103295000 USD
us-gaap Use Of Estimates
UseOfEstimates
<div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Use of Estimates</span></div><div style="text-indent:18pt;margin-bottom:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Management bases its estimates on certain assumptions which it believes are reasonable in the circumstances and while actual results could differ from those estimates, management does not believe that any change in those assumptions in the near term would have a significant effect on the Company’s financial position, results of operations or cash flows. Actual results in future periods could differ from those estimates.</span></div>
CY2020Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
2203000 USD
CY2019Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
481000 USD
CY2020Q2 us-gaap Interest Receivable
InterestReceivable
221000 USD
CY2019Q4 us-gaap Interest Receivable
InterestReceivable
236000 USD
CY2020Q2 us-gaap Prepaid Insurance
PrepaidInsurance
212000 USD
CY2019Q4 us-gaap Prepaid Insurance
PrepaidInsurance
533000 USD
CY2020Q2 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
952000 USD
CY2019Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
705000 USD
CY2020Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3588000 USD
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1955000 USD
CY2020Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
6108000 USD
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3416000 USD
CY2020Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1644000 USD
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1317000 USD
CY2020Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4464000 USD
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2099000 USD
CY2020Q2 us-gaap Depreciation Amortization And Accretion Net
DepreciationAmortizationAndAccretionNet
187000 USD
CY2019Q2 us-gaap Depreciation Amortization And Accretion Net
DepreciationAmortizationAndAccretionNet
87000 USD
us-gaap Depreciation Amortization And Accretion Net
DepreciationAmortizationAndAccretionNet
335000 USD
us-gaap Depreciation Amortization And Accretion Net
DepreciationAmortizationAndAccretionNet
174000 USD
CY2020Q2 us-gaap Restricted Cash
RestrictedCash
1200000 USD
CY2019Q4 us-gaap Restricted Cash
RestrictedCash
0 USD
CY2020Q2 xcur Prepaid Lease Costs
PrepaidLeaseCosts
823000 USD
CY2019Q4 xcur Prepaid Lease Costs
PrepaidLeaseCosts
0 USD
CY2020Q2 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
233000 USD
CY2019Q4 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
0 USD
CY2020Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
0 USD
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
356000 USD
CY2020Q2 us-gaap Other Assets Miscellaneous Noncurrent
OtherAssetsMiscellaneousNoncurrent
10000 USD
CY2019Q4 us-gaap Other Assets Miscellaneous Noncurrent
OtherAssetsMiscellaneousNoncurrent
32000 USD
CY2020Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2266000 USD
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
388000 USD
CY2020Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
706000 USD
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
920000 USD
CY2020Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
362000 USD
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
254000 USD
CY2020Q2 xcur Accrued Clinical Contract Research And Manufacturing Costs Current
AccruedClinicalContractResearchAndManufacturingCostsCurrent
303000 USD
CY2019Q4 xcur Accrued Clinical Contract Research And Manufacturing Costs Current
AccruedClinicalContractResearchAndManufacturingCostsCurrent
515000 USD
CY2020Q2 xcur Common Stock Warrant Liability Current
CommonStockWarrantLiabilityCurrent
257000 USD
CY2019Q4 xcur Common Stock Warrant Liability Current
CommonStockWarrantLiabilityCurrent
0 USD
CY2020Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
196000 USD
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
292000 USD
CY2020Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
123000 USD
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
454000 USD
CY2020Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1947000 USD
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2435000 USD
CY2020Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0 USD
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
59000 USD
CY2020Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
0 USD
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
59000 USD
xcur Debt Securities Available For Sale Current Percent
DebtSecuritiesAvailableForSaleCurrentPercent
0.92
xcur Debt Securities Available For Sale Noncurrent Percent
DebtSecuritiesAvailableForSaleNoncurrentPercent
0.08
xcur Debt Securities Availablefor Sale Percent
DebtSecuritiesAvailableforSalePercent
1
CY2020Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
68241000 USD
CY2020Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
342000 USD
CY2020Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
4000 USD
CY2020Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
68579000 USD
CY2019Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
64851000 USD
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
2000 USD
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
29000 USD
CY2019Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
64824000 USD
CY2020Q2 us-gaap Interest Paid Net
InterestPaidNet
0 USD
CY2019Q2 us-gaap Interest Paid Net
InterestPaidNet
152000 USD
us-gaap Interest Paid Net
InterestPaidNet
142000 USD
us-gaap Interest Paid Net
InterestPaidNet
301000 USD
xcur Lessee Operating Lease Lease Not Yet Commenced Lease Area
LesseeOperatingLeaseLeaseNotYetCommencedLeaseArea
30000 sqft
CY2020Q1 us-gaap Lessee Operating Lease Lease Not Yet Commenced Term Of Contract1
LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1
P10Y
CY2020Q1 xcur Lessee Operating Lease Lease Not Yet Commenced Numberof Extensions
LesseeOperatingLeaseLeaseNotYetCommencedNumberofExtensions
2 numberOfPeriods
CY2020Q1 us-gaap Lessee Operating Lease Lease Not Yet Commenced Renewal Term1
LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1
P5Y
CY2020Q1 xcur Lessee Operating Lease Lease Not Yet Commenced Annual Base Rate Initial Twelve Months
LesseeOperatingLeaseLeaseNotYetCommencedAnnualBaseRateInitialTwelveMonths
37.00
CY2020Q1 xcur Lessee Operating Lease Lease Not Yet Commenced Annual Rent Payment Initial Twelve Months
LesseeOperatingLeaseLeaseNotYetCommencedAnnualRentPaymentInitialTwelveMonths
1113000 USD
CY2020Q1 xcur Lessee Operating Lease Lease Not Yet Commenced Base Rent Annual Percentage Increase
LesseeOperatingLeaseLeaseNotYetCommencedBaseRentAnnualPercentageIncrease
0.03
CY2020Q1 xcur Lessee Operating Lease Lease Not Yet Commenced Estimated Rental Payment Over Original Term
LesseeOperatingLeaseLeaseNotYetCommencedEstimatedRentalPaymentOverOriginalTerm
12761000 USD
CY2020Q1 xcur Lessee Operating Lease Lease Not Yet Commenced Contribution Towards Tenant Improvement
LesseeOperatingLeaseLeaseNotYetCommencedContributionTowardsTenantImprovement
3159000 USD
CY2020Q1 us-gaap Letters Of Credit Outstanding Amount
LettersOfCreditOutstandingAmount
1200000 USD
CY2020Q1 xcur Lessee Operating Lease Lease Not Yet Commenced Rental Payment Adjusted For Abatement
LesseeOperatingLeaseLeaseNotYetCommencedRentalPaymentAdjustedForAbatement
87000 USD
xcur Lessee Operating Lease Lease Not Yet Commenced Contribution Towards Tenant Improvement
LesseeOperatingLeaseLeaseNotYetCommencedContributionTowardsTenantImprovement
736000 USD
CY2020Q1 us-gaap Letters Of Credit Outstanding Amount
LettersOfCreditOutstandingAmount
1200000 USD
CY2020Q2 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
211000 USD
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
147000 USD
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
59000 USD
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
206000 USD
CY2020Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
10000 USD
CY2020Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
196000 USD
CY2020Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
196000 USD
CY2020Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2020Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2020Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2020Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
87206346 shares
CY2020Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
87206346 shares
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
86069263 shares
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
86069263 shares
CY2020Q2 xcur Common Stock Voting Rightsfor Each Share
CommonStockVotingRightsforEachShare
1 vote_per_share
CY2020Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
3.00
CY2020Q2 us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
23000 USD
CY2020Q2 us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
6000 USD
CY2020Q2 us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
9404000 USD
CY2020Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
544000 USD
CY2019Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
439000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
985000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
928000 USD
CY2020Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
4893000 USD
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y10M24D
xcur Sharebased Compensation Arrangementby Sharebased Payment Award Fair Value Assumptions Forfeiture Rate
SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate
0.05
xcur Sharebased Compensation Arrangementby Sharebased Payment Award Fair Value Assumptions Forfeiture Rate
SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsForfeitureRate
0.05
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.29
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.99
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5697714 shares
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.34
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y8M12D
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
4625000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2075248 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.85
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
55899 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.89
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
18750 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
2.78
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7698313 shares
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.22
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y2M12D
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
4738000 USD
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
4372185 shares
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
2.12
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y6M
CY2020Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
3351000 USD
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
7442992 shares
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
2.22
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P7Y1M6D
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
4613000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
89000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
17000 USD
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-4311000 USD
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-5220000 USD
us-gaap Net Income Loss
NetIncomeLoss
-3161000 USD
us-gaap Net Income Loss
NetIncomeLoss
-10506000 USD
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
87174533 shares
CY2019Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
44368174 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
87126847 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
44363115 shares
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.05
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.12
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.04
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.24
xcur Fair Value Assumptions Impact Of10 Percent Change In Expected Volatility Rate
FairValueAssumptionsImpactOf10PercentChangeInExpectedVolatilityRate
33000 USD
xcur Fair Value Assumptions Impact Of10 Percent Change In Fair Value Of Common Stock
FairValueAssumptionsImpactOf10PercentChangeInFairValueOfCommonStock
59000 USD
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-157000 USD
xcur Paymentsfor License Agreements
PaymentsforLicenseAgreements
8229000 USD

Files In Submission

Name View Source Status
0001698530-20-000059-index-headers.html Edgar Link pending
0001698530-20-000059-index.html Edgar Link pending
0001698530-20-000059.txt Edgar Link pending
0001698530-20-000059-xbrl.zip Edgar Link pending
exicureexhibit102-empl.htm Edgar Link pending
exicureexhibit311-63020.htm Edgar Link pending
exicureexhibit312-63020.htm Edgar Link pending
exicureexhibit321-63020.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
xcur-20200630.htm Edgar Link pending
xcur-20200630.xsd Edgar Link pending
xcur-20200630_cal.xml Edgar Link unprocessable
xcur-20200630_def.xml Edgar Link unprocessable
xcur-20200630_g1.jpg Edgar Link pending
xcur-20200630_g2.jpg Edgar Link pending
xcur-20200630_htm.xml Edgar Link completed
xcur-20200630_lab.xml Edgar Link unprocessable
xcur-20200630_pre.xml Edgar Link unprocessable